文献速递临床试验与 GCP基础与转化研究

卡那奴单抗与安慰剂对重症COVID-19住院患者无创通气生存的影响:随机临床试验

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

这项在39家欧美医院开展的随机双盲安慰剂对照3期试验纳入454例重症COVID-19肺炎伴低氧血症和全身高炎症反应患者,比较单次静脉输注卡那奴单抗与安慰剂的效果。第3至29天,卡那奴单抗组无创机械通气生存率为88.8%,安慰剂组为85.7%,率差3.1%(95%CI -3.1%至9.3%;

要点

  • 卡那奴单抗未显著提高第29天无需有创机械通气的生存率。
  • 两组COVID-19相关死亡率分别为4.9%和7.2%,差异无统计学意义。
  • 卡那奴单抗组严重不良事件发生率16%,安慰剂组20.6%。

核心结论

  • 在重症COVID-19住院患者中,与安慰剂相比,卡那奴单抗未显著增加第29天无需有创机械通气的生存可能性。

研究设计与样本

  • 随机、双盲、安慰剂对照3期试验,在欧美39家医院开展。
  • 共纳入454例COVID-19肺炎、低氧血症(无需有创机械通气)且全身高炎症反应(血C反应蛋白或铁蛋白升高)的住院患者。
  • 患者按1:1随机接受单次静脉输注卡那奴单抗(体重40-<60 kg 450 mg,60-80 kg 600 mg,>80 kg 750 mg;n=227)或安慰剂(n=227)。
  • 主要终点为第3天至第29天无需有创机械通气的生存。

主要发现

  • COVID-19相关死亡:卡那奴单抗组223例中11例(4.9%),安慰剂组222例中16例(7.2%),率差-2.3%(95%CI -6.7%至2.2%),比值比0.67(95%CI 0.30至1.50)。
  • 严重不良事件:卡那奴单抗组225例中36例(16%),安慰剂组223例中46例(20.6%)。

临床怎么用

  • 对于重症COVID-19伴全身高炎症反应且无需有创机械通气的住院患者,卡那奴单抗未显示可显著改善无创通气生存结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effective treatments for patients with severe COVID-19 are needed. OBJECTIVE: To evaluate the efficacy of canakinumab, an anti-interleukin-1β antibody, in patients hospitalized with severe COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States. A total of 454 hospitalized patients with COVID-19 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin were enrolled between April 30 and August 17, 2020, with the last assessment of the primary end point on September 22, 2020. INTERVENTION: Patients were randomly assigned 1:1 to receive a single intravenous infusion of canakinumab (450 mg for body weight of 40-<60 kg, 600 mg for 60-80 kg, and 750 mg for >80 kg; n = 227) or placebo (n = 227). MAIN OUTCOMES AND MEASURES: The primary outcome was survival without IMV from day 3 to day 29. Secondary outcomes were COVID-19-related mortality, measurements of biomarkers of systemic hyperinflammation, and safety evaluations. RESULTS: Among 454 patients who were randomized (median age, 59 years; 187 women [41.2%]), 417 (91.9%) completed day 29 of the trial. Between days 3 and 29, 198 of 223 patients (88.8%) survived without requiring IMV in the canakinumab group and 191 of 223 (85.7%) in the placebo group, with a rate difference of 3.1% (95% CI, -3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76 to 2.54; P = .29). COVID-19-related mortality occurred in 11 of 223 patients (4.9%) in the canakinumab group vs 16 of 222 (7.2%) in the placebo group, with a rate difference of -2.3% (95% CI, -6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30 to 1.50). Serious adverse events were observed in 36 of 225 patients (16%) treated with canakinumab vs 46 of 223 (20.6%) who received placebo. CONCLUSIONS AND RELEVANCE: Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV at day 29. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04362813.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Caricchio R, Abbate A, Gordeev I, et al. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 34283183. doi:10.1001/jama.2021.9508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。